Stephen Whitehead

Type: Person
Name: Stephen Whitehead
First reported Aug 08 2014 - Updated Aug 08 2014 - 1 reports

ABPI comments on the value assessment of cancer medicines

Stephen Whitehead, ABPI Chief Executive, comments on the value assessment of cancer medicines. "We recognise that NICE frequently struggles with assessing the value of cancer and specialised medicines, hence the establishment of the Cancer Drugs Fund ... [Published Noodls - Aug 08 2014]
First reported Aug 07 2014 - Updated Aug 08 2014 - 1 reports

ROCHE BEARER SHARE : Sarah Boseley: Analysis This pharma fund is bad medicine

Roche , the Swiss pharmaceutical company at the centre of the row over cancer drugs pricing, played a significant part in the genesis of the Cancer Drugs Fund , set up in 2010 to pay for drugs that were too expensive for NHS approval. Four years on the ... [Published 4 Traders - Aug 07 2014]
First reported Aug 01 2014 - Updated Aug 02 2014 - 1 reports

Grimsby Telegraph published Sentenced: Grimsby man with out-of-control dog and washing powder...

The following people have been sentenced at Grimsby and Cleethorpes Magistrates Court.Marc Olley, 30, of Harrington Street, Cleethorpes, admitted assault by beating on June 15. He was committed to prison for 12-weeks, given a five-year restraining order ... [Published Grimsby Telegraph - Aug 01 2014]
First reported Jul 30 2014 - Updated Jul 30 2014 - 1 reports

Seven pharma companies offer up compounds to UK researchers

Business Secretary Vince Cable has announced that UK researchers will be granted access to a ‘virtual library’ of deprioritised pharmaceutical compounds through a new partnership between the Medical Research Council (MRC) and seven global drug compan ... [Published European Pharmaceutical Manufacturer - Jul 30 2014]
First reported Jul 26 2014 - Updated Jul 26 2014 - 1 reports

MRC Links With 7 Big Pharma Firms For Drug Research

By The Medical Research Council (MRC) has partnered with seven global big pharma firms to search new uses for deprioritized pharmaceutical compounds. These are AstraZeneca, Eli Lilly & Co., GlaxoSmithKline, Janssen R&D, Pfizer, Takeda, and UCB.British ... [Published Pharmaceutical Online - Jul 26 2014]
First reported Jul 24 2014 - Updated Jul 24 2014 - 2 reports

Seven pharma companies offer deprioritized compounds for re-purposing

U.K. researchers will be granted access to a ‘virtual library’ of deprioritized pharmaceutical compounds through a new partnership between the Medical Research Council (MRC) and seven global drug companies.AstraZeneca , GlaxoSmithKline , Janssen R&D , ... [Published Center Watch - Jul 24 2014]
First reported Jul 24 2014 - Updated Jul 24 2014 - 1 reports

ABPI establishes Inward Investor Group

The Association of the British Pharmaceutical Industry (ABPI) has established a new Inward Investor Group to demonstrate the importance of inward investment to the U.K. and the global mobility of such investment. The group also will work toward cultivating ... [Published Center Watch - Jul 24 2014]
First reported Jul 22 2014 - Updated Jul 22 2014 - 4 reports

Researchers Granted Access to Abandoned Compounds

The U.K.'s Medical Research Council (MRC) has inked a partnership with seven pharmaceutical firms—AstraZeneca, GlaxoSmithKline, Janssen Research & Development, Eli Lilly , Pfizer , Takeda , and UCB—giving U.K. researchers access to a virtual library of ... [Published Genetic Engineering News - Jul 22 2014]
First reported Jul 22 2014 - Updated Jul 22 2014 - 1 reports

Pharma bands together to attract UK investment

Industry leaders are banding together to help cultivate a more attractive environment in the UK for pharmaceutical companies to invest in.The Association of the British Pharmaceutical Industry has established a new Inward Investor Group currently including ... [Published Pharma Times - Jul 22 2014]
First reported Jul 21 2014 - Updated Jul 21 2014 - 1 reports

Become customer-centric by knowing who your customer is

There are different strategies for becoming customer-centric depending on whom your product benefits most. Although sometimes the interests of different stakeholders can be aligned, market prioritization remains important.In the discovery and development ... [Published eyeforpharma.com - Jul 21 2014]
First reported Jul 15 2014 - Updated Jul 16 2014 - 1 reports

Science minister leaves post

Science and engineering bodies today hailed the work of departing Science and Universities minister David Willetts, who was removedfrom his post by Prime Minister David Cameron in his cabinet reshuffle.Willetts led a number of initiatives to boost skills ... [Published Laboratorytalk - Jul 15 2014]
First reported Jul 11 2014 - Updated Jul 11 2014 - 1 reports

UK cancer patients face increasing coverage restriction, US report shows

New US research released yesterday quantifies the extent to which centralized value assessments by the UK’s health care cost watchdog National Institute for Health and Care Excellence (NICE) lead to coverage denials and patient access restrictions to ... [Published Pharma Letter - Jul 11 2014]

More Content

All (23) | News (22) | Reports (0) | Blogs (1) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
ABPI comments on the value assessment of cancer... [Published Noodls - Aug 08 2014]
ROCHE BEARER SHARE : Sarah Boseley: Analysis Th... [Published 4 Traders - Aug 07 2014]
ABPI president: NICE needs political reform [Published Pharmafocus - Aug 01 2014]
Grimsby Telegraph published Sentenced: Grimsby ... [Published Grimsby Telegraph - Aug 01 2014]
Seven pharma companies offer up compounds to UK... [Published European Pharmaceutical Manufacturer - Jul 30 2014]
MRC Links With 7 Big Pharma Firms For Drug Rese... [Published Pharmaceutical Online - Jul 26 2014]
ABPI establishes Inward Investor Group [Published Center Watch - Jul 24 2014]
Seven pharma companies offer deprioritized comp... [Published Center Watch - Jul 24 2014]
Pharma firms offer ‘deprioritised’ compounds [Published TCE Today - Jul 24 2014]
Seven pharma companies offer up compounds to UK... [Published AstraZeneca - Jul 22 2014]
Researchers Granted Access to Abandoned Compounds [Published Genetic Engineering News - Jul 22 2014]
Pharma bands together to attract UK investment [Published Pharma Times - Jul 22 2014]
Pharma firms to offer up compounds [Published Laboratorytalk - Jul 22 2014]
Pharma firms open up drug libraries to UK resea... [Published PMLive - Jul 22 2014]
Pharma pact with MRC to 'repurpose' stalled com... [Published Pharma Times - Jul 22 2014]
Become customer-centric by knowing who your cus... [Published eyeforpharma.com - Jul 21 2014]
Science minister leaves post [Published Laboratorytalk - Jul 15 2014]
UK cancer patients face increasing coverage res... [Published Pharma Letter - Jul 11 2014]
Doctors advised against aspirin for patients wi... [Published Guardian.co.uk - Jun 18 2014]
ABPI welcomes Department of Health’s decision t... [Published PharmiWeb - Apr 15 2014]
GSK Poland - Shelley Jofre writes in the BMJ [Published PharmaGossip - Apr 14 2014]
Fish rot from the head [Published open Democracy News Analysis - - Mar 20 2014]
ABPI comments on the Prime Minister's speech to... [Published PharmiWeb - Dec 11 2013]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
GSK Poland - Shelley Jofre writes in the BMJ [Published PharmaGossip - Apr 14 2014]
Shelley Jofre, BBC Panorama correspondent shelley.jofre@bbc.co.uk The company may have broken US and UK laws on bribery, says  Shelley Jofre GlaxoSmithKline (GSK) recently announced that by 2016 it will end direct payments to doctors for promotional talks ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.